Topics:
ARS 2014|Breast Cancer|Colorectal Cancer|Leukemia & Lymphoma|Lung Cancer|Melanoma|ASCO 2014|Prostate Cancer|Browse All Topics

Multiple Myeloma

Stringent Complete Response in Multiple Myeloma Associated With Best Survival Outcomes

Patients able to achieve stringent complete response after undergoing autologous stem-cell transplantation for multiple myeloma achieved improved long-term outcomes, including overall survival and time to progression, compared with patients who achieved lesser levels of response.

Multiple Myeloma

Myeloma Working Group Releases Statement on Use of MRI

Leah Lawrence
News | January 23, 2015 | Multiple Myeloma, Hematologic Malignancies
By

The International Myeloma Working Group recently published a series of consensus statements discussing the use of MRI in the treatment of multiple myeloma.

Higher Bortezomib Dose Upped Multiple Myeloma Survival

Leah Lawrence
News | January 13, 2015 | Multiple Myeloma, Hematologic Malignancies
By

A new trial reported improved overall survival in myeloma patients who received a higher bortezomib dose as part of a bortezomib/melphalan/prednisone regimen.

Smoking Not a Risk Factor for Multiple Myeloma

Leah Lawrence
News | January 07, 2015 | Multiple Myeloma, Hematologic Malignancies
By

Cigarette smoking is not a risk factor for multiple myeloma, according to the results of a pooled analysis of nine case-control studies.

Daratumumab Safe With Myeloma Backbone Therapies

Leah Lawrence
News | December 16, 2014 | Multiple Myeloma, ASH 2014, Hematologic Malignancies
By

The addition of daratumumab to traditional therapies used in the treatment of multiple myeloma was well tolerated and associated with high rates of responses.

New Developments in Multiple Myeloma

Noopur Raje, MD
December 08, 2014 | ASH 2014, Hematologic Malignancies, Multiple Myeloma
By

In this podcast from the 2014 American Society of Hematology Annual Meeting, we discuss some of the new developments in multiple myeloma.

Adding Carfilzomib to Myeloma Treatment Results in ‘Unprecedented’ Boost in PFS

Anna Azvolinsky, PhD
News | December 08, 2014 | ASH 2014, Hematologic Malignancies, Multiple Myeloma
By

Adding carfilzomib to lenalidomide and dexamethasone resulted in a higher PFS and better overall quality of life for relapsed multiple myeloma patients.

Data Supports Ixazomib for Phase III Myeloma Trial

Leah Lawrence
News | December 02, 2014 | Multiple Myeloma, Hematologic Malignancies
By

Early trial data support further evaluation of ixazomib combined with lenalidomide and dexamethasone for the treatment of newly diagnosed multiple myeloma.

Pages

Subscribe to Multiple Myeloma on [sitename]
View More Podcasts

By clicking Accept, you agree to become a member of the UBM Medica Community.